Progression-Free Survival Common For Pregnant Women For pregnant HIV-infected women with access to highly active antiretroviral therapy (HAART), the medium-term postpartum prognosis is good, according to a report in the October 1st Journal of Acquired Immune Deficiency Syndromes.
October 27, 2006
Tyzeka Approved for Hepatitis B
The U.S. Food and Drug Administration (FDA) granted approval on Wednesday to Tyzeka? (telbivudine), a new treatment for chronic hepatitis B virus (HBV) infection.
October 26, 2006
Vaccine Series Safe In Children Pneumococcal conjugate vaccine (PCV) followed by pneumococcal polysaccharide vaccine (PPV) appears to be safe and effective for certain HIV-infected children, researchers report in the October issue of the Pediatric Infectious Disease Journal.
October 24, 2006
Vulnerable HIV Patients Less Likely To Have Care Members of minority groups, who are most at risk of contracting HIV infection and most likely to be in greatest need of service, are also the individuals who are least likely to be receiving medical care in the U.S., investigators report.
Enfuvirtide As Rescue Therapy
Findings from a small study suggest that the fusion inhibitor enfuvirtide (formerly T-20) is a useful therapeutic option for multi-class experienced HIV-infected patients.
October 20, 2006
New 300mg Reyataz Capsule Approved Bristol-Myers Squibb announced today that it has received U.S. Food and Drug Administration (FDA) approval for a 300mg capsule version of its protease inhibitor Reyataz® (atazanavir). For HIV-positive people combining Reyataz with Norvir® (ritonavir), the 300mg Reyataz capsule can be used in place of the two 150mg capsules currently recommended when both drugs are taken together.
Anal HPV Infection Common in Women
Human papillomavirus (HPV) infection of the anus is more common than HPV infection of the cervix in HIV-positive women, according to new data reported last week at the 44th Annual Meeting of the Infectious Disease Society of America (IDSA) in Toronto.
Bacteria Protein Prevents HIV Entry
The binding domain from Porphyromonas gingivalis gingipain prevents cell entry by HIV-1, according to a report in the September issue of Antimicrobial Agents and Chemotherapy.
October 10, 2006
New U.S. Treatment Guidelines
Norvir (ritonavir)-boosted Reyataz (atazanavir) and Lexiva (fosamprenavir) are comparable to Kaletra (lopinavir/ritonavir) as "preferred" protease inhibitor (PI) options for HIV-positive people starting therapy for the first time, according to new federal treatment guidelines issued by the U.S. Department of Health and Human Services (DHHS).
Tenofovir Prodrug Delays SHIV Infection
Nearly two-thirds of patients with HIV-associated dementia have actively changing cognitive status; the neurological status in the majority of these patients deteriorates but a significant minority improves, according to data presented here at the annual meeting of the American Neurological Association.
Course Of HIV Neurologic Disease Variable, Related To Platelet Count Nearly two-thirds of patients with HIV-associated dementia have actively changing cognitive status; the neurological status in the majority of these patients deteriorates but a significant minority improves, according to data presented here at the annual meeting of the American Neurological Association.
October 06, 2006
First Test for Early HIV Infection
The U.S. Food and Drug Administration has announced the approval of Aptima®, a new assay that can be used to aid the detection of HIV in those who may be newly infected with the virus and cannot yet depend on the results of antibody testing.
Diary of a Doc: Vaccine Update at ICAAC
Developing a vaccine to prevent HIV infection has been a significant challenge, and, sadly, traditional vaccines are not expected to reach clinical use for another ten years.
Medecins Sans Frontieres Founder Wants Stronger WHO The United Nations cannot take a backseat to private philanthropic foundations and needs more money to combat diseases like malaria and tuberculosis, the French candidate to lead the World Health Organisation (WHO) said on Thursday.
Boosted Atazanavir Of Mixed Benefit In Pediatric HIV Switching to a once daily-regimen including ritonavir-boosted atazanavir appears helpful in some HIV-infected children, but has led to unexpected virological failure in others, according to French researchers
ICAAC: Norvir-Boosted Lexiva vs. Reyataz
Early data from a study comparing Lexiva (fosamprenavir) to Reyataz (atazanavir), both combined with low-dose Norvir (ritonavir), suggest that both drugs have similar effectiveness.
More Treatment News
Have news about HIV? Send press releases, news tips and other announcements to email@example.com.